Executive Summary
This digest covers a single $290.9 million civilian mega-contract awarded to Walgreens Boots Alliance by the CDC under the ICATT program, representing 100% non-defense spending. The contract is fully obligated and outlayed, providing high near-term revenue visibility through May 2025, but its firm-fixed-price structure introduces medium execution risk.
The highest-conviction signal is the bullish revenue certainty for Walgreens, though the absence of defense exposure and the single-contract concentration limit broader sector implications. Key watch items include CDC budget allocations for ICATT in FY2025-2026 and potential competitor wins that could signal market share shifts.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Mega Contracts Monitor ($100M+) digest from September 02, 2026.
Investment Signals (1)
- Walgreens Wins $290.9M CDC ICATT Contract, Bolstering Near-Term Revenue Visibility (HIGH)▲
Walgreens secured a fully obligated, firm-fixed-price contract from the CDC for specialized medical support, providing $96.9 million in annualized revenue through May 2025. The full-and-open competitive award signals merit-based selection, though fixed-price terms carry margin risk.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
The firm-fixed-price structure of Walgreens' $290.9M CDC contract creates execution risk if costs exceed projections, potentially compressing margins on the $96.9M annual revenue stream.
- Concentration [MEDIUM RISK]▼
This single $290.9M contract represents 100% of the digest's total obligation, creating concentration risk for Walgreens if the ICATT program faces budget cuts or non-renewal after May 2025.
Opportunities (1)
- ◆
Walgreens' competitive win of a $290.9M CDC contract under full-and-open competition demonstrates ability to expand in federal civilian health services, potentially opening doors to follow-on awards or similar HHS contracts.
Sector Themes (1)
- ◆
The fully obligated $290.9M CDC contract to Walgreens underscores continued federal investment in specialized medical support services, even amid broader budget uncertainty. This contrasts with defense contracts that face higher CR vulnerability in Q4.
Watch List (3)
- 👁
{"entity" => "Walgreens Boots Alliance (WBA)", "reason" => "Single $290.9M CDC contract provides 12% of annual revenue estimate; renewal or loss materially impacts federal revenue stream.", "trigger" => "CDC ICATT program re-compete announcement or FY2025 budget release"}
- 👁
{"entity" => "CDC ICATT program", "reason" => "Budget allocation changes directly affect Walgreens' contract durability and potential follow-on awards.", "trigger" => "FY2025 and FY2026 CDC budget requests"}
- 👁
{"entity" => "CVS Health (CVS)", "reason" => "As a competitor in pharmacy-based health services, CVS could win similar CDC contracts, signaling market share shifts.", "trigger" => "Competitor CDC contract announcements"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Mega Contracts Monitor ($100M+)
🇺🇸 More from United States
View all →September 03, 2026
US Pre-Market SEC Filings Roundup — September 03, 2026
US Pre-Market SEC Filings Roundup
September 03, 2026
USA Corporate Events Calendar — September 03, 2026
USA Corporate Events Calendar
September 03, 2026
USA Earnings Calls Schedule — September 03, 2026
USA Earnings Calls Schedule
September 03, 2026
US Merger & Acquisition SEC Filings — September 03, 2026
US Merger & Acquisition SEC Filings